FibroGen, Inc. (NASDAQ:FGEN) Sees Significant Drop in Short Interest

FibroGen, Inc. (NASDAQ:FGEN) was the recipient of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,910,000 shares, a decrease of 5.2% from the January 15th total of 3,070,000 shares. Based on an average daily volume of 1,250,000 shares, the short-interest ratio is presently 2.3 days.

FibroGen Stock Performance

NASDAQ FGEN opened at $0.56 on Thursday. The stock has a market capitalization of $56.63 million, a P/E ratio of -0.46 and a beta of 0.75. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80. The business’s fifty day moving average is $0.51 and its two-hundred day moving average is $0.42.

Wall Street Analyst Weigh In

FGEN has been the subject of a number of research analyst reports. StockNews.com initiated coverage on FibroGen in a research report on Thursday, February 13th. They issued a “hold” rating for the company. William Blair restated a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. Finally, HC Wainwright raised FibroGen to a “strong-buy” rating in a report on Tuesday, December 17th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in shares of FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 32,884 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in FibroGen during the 4th quarter valued at $27,000. FMR LLC raised its stake in FibroGen by 21.8% during the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares during the period. XTX Topco Ltd raised its stake in FibroGen by 423.8% during the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 77,693 shares during the period. Finally, Velan Capital Investment Management LP acquired a new stake in FibroGen during the 4th quarter valued at $42,000. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.